Assessing Particle Size and Surface Charge in Drug Carrier Nanoparticles for Enhanced Cancer Treatment: A Comprehensive Review Utilizing DLS and Zeta Potential Characterization

Abstract

The provided information underscores the significance of cancer control, including early detection, treatment, and prevention. The World Health Organization (W.H.O) is actively working towards improving access to screening, prevention, and treatment services, as well as raising awareness about the importance of cancer prevention and early detection. Researchers are also exploring the potential of natural substances to develop safer drugs for cancer treatment, with the W.H.O providing support to organizations involved in this research. One approach being explored is the use of Drug Delivery Systems (DDSs) to minimize damage to healthy tissue during cancer treatment. Maintaining a Zeta potential range between -30 and +30mV is considered optimal for nanocarriers in the bloodstream, as it ensures stability and long-term activity. Additionally, nanoparticles with a size below 200nm can be effectively distributed in the body and have an increased penetration rate into cancer cells. Smaller particles exhibit better mobility and can more efficiently reach their targets. A recent study analyzed the particle size and surface charge of newly designed drug nanocarriers to improve cancer treatment. This promising approach aims to optimize drug delivery and enhance the efficacy of cancer therapy.